%0 Journal Article
%T AP-2α gene deregulation is associated with renal cell carcinoma patient survival.
%A Lin PH
%A Hsieh CH
%A Yu KJ
%A Shao IH
%A Chuang CK
%A Hsu T
%A Weng WH
%A Pang ST
%J BMC Cancer
%V 24
%N 1
%D 2024 Aug 7
%M 39112969
%F 4.638
%R 10.1186/s12885-024-12526-w
%X <B>BACKGROUND: </B>Renal cell carcinoma (RCC), one of the most fatal urologic tumors, accounts for approximately 3% of all adult cancers and exhibits a high metastatic index at diagnosis and a high rate of relapse. Radical or partial nephrectomy is a curative option for nonmetastatic RCCs. Targeted therapy has been shown to improve the survival of patients with metastatic RCCs. However, the underlying cellular and molecular events associated with RCC pathogenesis are not well known.<BR><B>METHODS: </B>To investigate the clinical role of the transcription factor activator protein (AP)-2α in RCC, methylated CpG island recovery assays and microarray analysis were employed. COBRA and RT‒qPCR assays were performed to assess AP-2α expression in RCC.<BR><B>RESULTS: </B>A negative correlation was noted between AP-2α mRNA expression levels and methylation status. Multivariate analyses showed that AP-2α mRNA was a major risk factor not only for overall and disease-free survival in RCC but also for disease-free survival in clear cell RCC.<BR><B>CONCLUSIONS: </B>Our results indicated that AP-2α expression was deregulated in RCC and associated with overall patient survival and disease-free survival. Such findings suggest that AP-2α might play an important role in the pathogenesis of RCC.